July 2012 www.PharmacyTimes.com 117
December 2015 PharmacyTimes.org 117
References
1. Oge LK, Muncie HL, Phillips-Savoy AR. Rosacea:
diagnosis and treatment. Am Fam Physician.
2015;92(3):187-196.
2. Elewski BE, Draelos Z, Dréno B, Jansen T, Layton A,
Picardo M. Rosacea—global diversity and optimized
outcome: proposed international consensus from the
Rosacea International Expert Group. J Eur Acad
Dermatol Venereol. 2011;25(2):188-200.
3. Marks R. The enigma of rosacea. J Dermatolog Treat.
2007;18(6):326-328.
4. Del Rosso JQ. Advances in understanding and man-
aging rosacea: part 1. J Clin Aesthet Dermatol.
2012;5(3):16-25.
5. Two AM, Wu W, Gallo RL, Hata TR. Part I.
Introduction, categorization, histology, patho-
genesis, and risk factors. J Am Acad Dermatol.
2015;72(5):749-758. doi: 10.1016/j.jaad.2014.08.028.
6. Lanoue J, Goldenberg G. Therapies to improve the
cosmetic symptoms of rosacea. Cutis. 2015;96(7):19-
26.
7. Weinkle AP, Doktor V, Emer J. Update on the man-
agement of rosacea. Clin Cosmetic Investig Dermatol.
2015;8:159-177. doi: 10.2147/CCID.S58940.
8. Tan J, Berg M. Rosacea: current state of epidemiol-
ogy. J Am Acad Dermatol. 2013;69(6 [suppl 1]):S27-
35. doi: 10.1016/j.jaad.2013.04.043.
9. Kuo S, Huang KE, Davis SA, Feldman SR. The
rosacea patient journey: a novel approach to concep-
tualizing patient experiences. Cutis 2015;95(1):37-43.
10. National Rosacea Society study reveals social impact
of condition on patients. Cutis. 2013;4:91(3).
11. Moustafa F, Lewallen RS, Feldman SR. The psy-
chological impact of rosacea and the influence of
current management options. J Am Acad Dermatol.
2014;71(5):973-980. doi: 10.1016/j.jaad.2014.05.036.
12. Wilkin J, Dahl M, Detmar M, et al. Standard clas-
sification of rosacea: report of the National Rosacea
Society Expert Committee on the Classification
and Staging of Rosacea. J Am Acad Dermatol.
2002;46(4):584-587.
13. Wilkin J, Dahl M, Detmar M, et al. Standard grading
system for rosacea: report of the National Rosacea
Society Expert Committee on the Classification
and Staging of Rosacea. J Am Acad Dermatol.
2004;50(6):907-912.
14. The many faces of rosacea. National Rosacea Society
website. rosacea.org/patients/faces.php. Accessed
October 8, 2015.
15. Vieira AC, Mannis MJ. Ocular rosacea: common and
commonly missed. J Am Acad Dermatol. 2013;69(6
[suppl 1]):S36-S41. doi: 10.1016/j.jaad.2013.04.042.
16. Rosacea triggers survey. National Rosacea Society
website. rosacea.org/patients/materials/triggersgraph.
php. Accessed September 10, 2015.
17. Factors that may trigger rosacea flare-ups. National
Rosacea Society website. rosacea.org/patients/materi-
als/triggers.php. Accessed September 15, 2015.
18. Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part
II. Topical and systemic therapies in the treatment of
rosacea. J Am Acad Dermatol. 2015;72(5):761-770.
doi: 10.1016/j.jaad.2014.08.027.
19. Hawkins SS, Subramanyan K, Liu D, Bryk M.
Cleansing, moisturizing, and sun-protection regimens
for normal skin, self-perceived sensitive skin, and
dermatologist-assessed sensitive skin. Dermatol Ther.
2004;17(suppl 1):63-68.
20. Levin J, Miller R. A guide to the ingredients and
potential benefits of over-the-counter cleansers and
moisturizers for rosacea patients. J Clin Aesthet
Dermatol. 2011;4(8):31-49.
21. Makeup for rosacea. National Rosacea Society web-
site. rosacea.org/patients/skincare/makeuptips.php.
Accessed September 10, 2015.
22. Baldwin HE, Harper JC. Improving management
of rosacea: from therapeutics to routine skin care.
Medscape website. medscape.org/viewarticle/835995.
Published December 9, 2014. Accessed September
15, 2015.
23. Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus
recommendations from the American Acne & Rosacea
Society on the management of rosacea, part 2: a status
report on topical agents. Cutis. 2013;92(6):277-284.
24. For men: shaving tips for skin with rosacea. National
Rosacea Society website. rosacea.org/patients/skin-
care/shavingtips.php. Accessed October 6, 2015.
25. Coda AB, Hata T, Miller J, et al. Cathelicidin, kal-
likrein 5, and serine protease activity is inhibited
during treatment of rosacea with azalaic acid 15%
gel. J Am Acad Dermatol. 2013;69(4):570-577. doi:
10.1016/j.jaad.2013.05.019.
26. van Zuuren EJ, Kramer SF, Carter BR, Graber MA,
Fedorowicz Z. Effective and evidence-based manage-
ment strategies for rosacea: summary of a Cochrane
systematic review. Br J Dermatol. 2011;165(4):760-
781. doi: 10.1111/j.1365-2133.2011.10473.x.
27. Elewski BE, Fleisher AB, Pariser DM. A comparison
of 15% azelaic acid gel and 0.75% metronidazole
gel in the topical treatment of papulopustular rosa-
cea: results of a randomized trial. Arch Dermatol.
2003;139(11):1444-1450.
28. Maddin S. A comparison of topical azelaic acid 20%
cream and topical metronidazole 0.75% cream in the
treatment of patients with papulopustular rosacea. J
Am Acad Dermatol. 1999;40(6 pt 1):961-965.
29. Del Rosso JQ. A status report on the medical manage-
ment of rosacea: focus on topical therapies. Cutis.
2002;70(5):271-275.
30. Tanghetti EA, Jackson JM, Belasco KT, et al.
Optimizing the use of topical brimonidine in rosa-
cea management: panel recommendations. J Drugs
Dermatol. 2015;14(1):33-40.
31. Fowler J, Jarratt M, Moore A, et al; Brimonidine
Phase III Study Group. Once-daily topical brimoni-
dine tartrate gel 0.5% is a novel treatment of mode-
rate to severe facial erythema of rosacea: results of
two multicenter, randomized and vehicle-controlled
studies. Br J Dermatol. 2012;166(3):633-641. doi:
10.1111/j.1365-2133.2011.10716.x.
32. Fowler J Jr, Jackson JM, Moore A, et al. Efficacy and
safety of once-daily brimonidine tartrate gel 0.5% for
the treatment of moderate to severe facial erythema of
rosacea: results of two randomized, double-blind, and
vehicle-controlled pivotal studies. J Drugs Dermatol.
2013;12(6):650-656.
33. Routt ET, Levitt JO. Rebound erythema and burning
sensation from a new topical brimonidine tartrate gel
0.33%. J Am Acad Dermatol. 2014;70(2):e37-38. doi:
10.1016/j.jaad.2013.10.054.
34. Ilkovitch D, Pomerantz RG. Brimonidine effective but
may lead to significant rebound erythema. J Am Acad
Dermatol. 2014;70(5):e109-e110. doi: 10.1016/j.
jaad.2014.01.853.
35. Johnson AW, Johnson SM. The role of topical brimo-
nidine tartrate gel as a novel therapeutic option for
persistent facial erythema associated with rosacea.
Dermatol Ther (Heidelb). 2015;5(3):171-181. doi:
10.1007/s13555-015-0078-1.
36. Stein L, Kircik L, Fowler J, et al. Efficacy and safety
of ivermectin 1% cream in treatment of papulopustu-
lar rosacea: results of two randomized, double-blind,
vehicle-controlled pivotal studies. J Drugs Dermatol.
2014;13(3):316-323.
37. Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus
recommendations from the American Acne & Rosacea
Society on the management of rosacea, part 3: a status
report on systemic agents. Cutis. 2014;93(1):18-28.
38. Park H, Del Rosso JQ. Use of oral isotretinoin in the
management of rosacea. J Clin Aesthet Dermatol.
2011;4(9):54-61.
39. Hsu C-C, Lee Y-Y. Carvedilol for the treatment of
refractory facial flushing and persistent erythema of
rosacea. Arch Dermatol. 2011;147(11):1258-1260.
doi: 10.1001/archdermatol.2011.204.
40. Del Rosso JQ, Thiboutot D, Gallo R, et al; American
Acne & Rosacea Society. Consensus recommenda-
tions from the American Acne & Rosacea Society
on the management of rosacea, part 5: a guide on the
management of rosacea. Cutis. 2014;93(3):134-138.
41. Tanghetti E, Del Rosso JQ, Thiboutot D, et al;
American Acne & Rosacea Society. Consensus rec-
ommendations from the American Acne & Rosacea
Society on the management of rosacea, part 4: a status
report on physical modalities and devices. Cutis.
2014;93(2):71-76.
42. Odom R, Dahl M, Dover J, et al; National Rosacea
Society Expert Committee on the Classification and
Staging of Rosacea. Standard management options for
rosacea, part 2: options according to subtype. Cutis.
2009;84(2):97-104.
43. National survey reveals that rosacea sufferers often
hide behind cosmetics before treating the condition
[press release]. Ft. Worth, TX: National Rosacea
Society; May 28, 2015. rosacea.org/press/national-
survey-reveals-rosacea-sufferers-often-hide-behind-
cosmetics-treating-condition. Accessed September
10, 2015.
44. DelRosso JQ. Management of rosacea in the United
States: analysis based on recent prescribing pat-
terns and insurance claims. J Am Acad Dermatol.
2008;58(2):AB13.
Educational Disclaimer: Continuing professional education (CPE) activities sponsored by Pharmacy Times Offce of CPE are offered solely for educational
purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may refect the clinical
experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature
and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
INSTRUCTIONS FOR EARNING CREDIT
• Begin the activity by reading the
content in its entirety.
• Go to PharmacyTimes.org to access
the posttest and activity evaluation
form.
• Complete the electronic posttest
and activity evaluation form.
• Once completed, click on "submit
posttest." Your posttest will auto-
matically be graded.
• If you successfully complete the
posttest (score of 70% or higher)
and the evaluation form, this
information will be uploaded into
CPE Monitor.
• You must complete these steps
before the activity expires in order
to receive your credit.
• You may view your credit within
48 hours at www.mycpemonitor.
net.